Summary This International Myeloma Working Group consensus updates the disease
definition of multiple myeloma to include validated biomarkers in addition to existing …

The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background Monoclonal gammopathy of undetermined significance (MGUS) occurs in
approximately 3% of persons 50 years of age or older. Methods We studied 1384 patients …

The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …

Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

Interleukin-1 beta (IL-1β) is induced by inflammatory signals in a broad number of immune
cell types. IL-1β (and IL-18) are the only cytokines which are processed by caspase-1 after …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple
myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of …